Tags

Type your tag names separated by a space and hit enter

The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Br J Pharmacol. 2020 11; 177(21):4845-4850.BJ

Abstract

Coronavirus disease 2019 (COVID-19), the disease resulting from infection by a novel coronavirus, SARS-Cov2, has rapidly spread since November 2019 leading to a global pandemic. SARS-Cov2 has infected over four million people and caused over 290,000 deaths worldwide. Although most cases are mild, a subset of patients develop a severe and atypical presentation of acute respiratory distress syndrome (ARDS) that is characterised by a cytokine release storm (CRS). Paradoxically, treatment with anti-inflammatory agents and immune regulators has been associated with worsening of ARDS. We hypothesize that the intrinsic circadian clock of the lung and the immune system may regulate individual components of CRS, and thus, chronotherapy may be used to effectively manage ARDS in COVID-19 patients. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada. College of Dental Medicine, Qatar University, Doha, Qatar.Faculty of Dentistry, McGill University, Montreal, Quebec, Canada.Divisions of Critical Care, Pulmonary and Sleep Medicine, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.Divisions of Critical Care, Pulmonary and Sleep Medicine, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA. Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32442317

Citation

Tamimi, Faleh, et al. "The Case for Chronotherapy in Covid-19-induced Acute Respiratory Distress Syndrome." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4845-4850.
Tamimi F, Abusamak M, Akkanti B, et al. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome. Br J Pharmacol. 2020;177(21):4845-4850.
Tamimi, F., Abusamak, M., Akkanti, B., Chen, Z., Yoo, S. H., & Karmouty-Quintana, H. (2020). The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome. British Journal of Pharmacology, 177(21), 4845-4850. https://doi.org/10.1111/bph.15140
Tamimi F, et al. The Case for Chronotherapy in Covid-19-induced Acute Respiratory Distress Syndrome. Br J Pharmacol. 2020;177(21):4845-4850. PubMed PMID: 32442317.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome. AU - Tamimi,Faleh, AU - Abusamak,Mohammad, AU - Akkanti,Bindu, AU - Chen,Zheng, AU - Yoo,Seung-Hee, AU - Karmouty-Quintana,Harry, Y1 - 2020/07/03/ PY - 2020/04/26/received PY - 2020/05/07/revised PY - 2020/05/09/accepted PY - 2020/5/23/pubmed PY - 2020/10/28/medline PY - 2020/5/23/entrez SP - 4845 EP - 4850 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - Coronavirus disease 2019 (COVID-19), the disease resulting from infection by a novel coronavirus, SARS-Cov2, has rapidly spread since November 2019 leading to a global pandemic. SARS-Cov2 has infected over four million people and caused over 290,000 deaths worldwide. Although most cases are mild, a subset of patients develop a severe and atypical presentation of acute respiratory distress syndrome (ARDS) that is characterised by a cytokine release storm (CRS). Paradoxically, treatment with anti-inflammatory agents and immune regulators has been associated with worsening of ARDS. We hypothesize that the intrinsic circadian clock of the lung and the immune system may regulate individual components of CRS, and thus, chronotherapy may be used to effectively manage ARDS in COVID-19 patients. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32442317/The_case_for_chronotherapy_in_Covid_19_induced_acute_respiratory_distress_syndrome_ L2 - https://doi.org/10.1111/bph.15140 DB - PRIME DP - Unbound Medicine ER -